Lannion,
2021 FIRST-HALF REVENUES: €75.5M, +13% PRO FORMA1
Consolidated revenues (unaudited)
Revenues (€m) | 2021 | 2020 | Reported change | pro forma 2020 1 | Pro forma 1 change |
First quarter | 33.8 | 21.9 | +54% | 32.7 | +3.2% |
Second quarter | 41.7 | 23.9 | +75% | 33.8 | +23% |
First half | 75.5 | 45.8 | +65% | 66.6 | +13% |
of which | |||||
Photonics | 34.7 | 29.9 | +16% | 29.9 | +16% |
Medical | 40.8 | 15.8 | +158% | 36.7 | +11% |
The LUMIBIRD Group’s consolidated revenues for the first six months of 2021 climbed to €75.5m, up 65% based on reported data and +13% pro forma, including Ellex’s laser and ultrasound activities at
For the Photonics division, the Industrial and Scientific business is continuing to see strong growth (+39% to €17.1m), thanks in particular to the acceleration of OEM sales for medical and flatscreen applications. The Lidar business (-17% to €7.4m) is building on the trend from the first quarter, marked by an upturn in sales of lasers to integrators, particularly in the autonomous vehicle sector, offset by a contraction in deliveries of Lidar systems to end users, due to sourcing delays. The Defense / Space business, freed up from the base effect linked to the MegaJoule contract, is reporting significant progress (+18% to €10.1m).
The Medical division achieved +158% growth based on reported data and +11% pro forma. Adjusted for foreign exchange effects and the Libyan contract for €0.85m, pro forma growth came to 16%. The strong progress with the Medical business during the second quarter (+25% pro forma) reflects the catch-up effect compared with the period that was relatively marked by the health crisis in 2020, as well as the continued deployment of commercial synergies supporting cross-selling for the
Following double-digit organic growth for the first half of the year,
Next date:
2021 half-year earnings on
Born from the combination of
Contacts
Chairman and CEO Tel. +33(0) 1 69 29 17 00 info@lumibird.com | Aude Nomblot-Gourhand Secretary General – CFO Tel. +33(0) 1 69 29 17 00 info@lumibird.com | Calyptus Investors Relations Tel. +33(0) 1 53 65 37 91 lumibird@calyptus.net |
1 Including Ellex at
Attachment
- 210726_Lumibird_CAS12021_EN
© OMX, source